Target

Caspase-2

Novel target differentiated from NASH competitors

• Activation drives lipogenesis and steatohepatitis
• Induced by ER stress and TNF
• Proteolytic activation of S1P and activation of SREBP
• Inhibition halts progression of NASH
• Therapeutics against caspase-2 can be used to prevent and treat stress-driven fatty liver diseases
• SBDD and biologic technologies can be applied